Luyan Pharma Co.,Ltd. (002788.SZ)
CNY 8.76
(0.0%)
CNY 8.76
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.81 Billion CNY | -1.96% |
| 2022 | 8.99 Billion CNY | 21.0% |
| 2021 | 7.43 Billion CNY | 23.29% |
| 2020 | 6.02 Billion CNY | 6.7% |
| 2019 | 5.64 Billion CNY | 27.92% |
| 2018 | 4.41 Billion CNY | 23.86% |
| 2017 | 3.56 Billion CNY | 67.16% |
| 2016 | 2.13 Billion CNY | -20.49% |
| 2015 | 2.68 Billion CNY | 0.69% |
| 2014 | 2.66 Billion CNY | 17.5% |
| 2013 | 2.26 Billion CNY | 27.67% |
| 2012 | 1.77 Billion CNY | 82.53% |
| 2011 | 973.16 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 8.81 Billion CNY | -1.8% |
| 2024 Q3 | 9.29 Billion CNY | 5.43% |
| 2024 Q1 | 8.97 Billion CNY | 1.83% |
| 2023 Q3 | 8.53 Billion CNY | -1.09% |
| 2023 Q4 | 8.81 Billion CNY | 3.24% |
| 2023 FY | 8.81 Billion CNY | -1.96% |
| 2023 Q1 | 8.48 Billion CNY | -5.61% |
| 2023 Q2 | 8.63 Billion CNY | 1.71% |
| 2022 Q4 | 8.99 Billion CNY | 11.53% |
| 2022 Q3 | 8.06 Billion CNY | 2.46% |
| 2022 Q2 | 7.86 Billion CNY | -0.18% |
| 2022 Q1 | 7.88 Billion CNY | 6.08% |
| 2022 FY | 8.99 Billion CNY | 21.0% |
| 2021 Q1 | 6.43 Billion CNY | 6.74% |
| 2021 Q2 | 6.6 Billion CNY | 2.58% |
| 2021 Q3 | 7.04 Billion CNY | 6.76% |
| 2021 Q4 | 7.43 Billion CNY | 5.47% |
| 2021 FY | 7.43 Billion CNY | 23.29% |
| 2020 Q4 | 6.02 Billion CNY | 0.28% |
| 2020 Q1 | 5.78 Billion CNY | 2.44% |
| 2020 Q2 | 6 Billion CNY | 3.82% |
| 2020 FY | 6.02 Billion CNY | 6.7% |
| 2020 Q3 | 6.01 Billion CNY | 0.04% |
| 2019 Q4 | 5.64 Billion CNY | 3.57% |
| 2019 FY | 5.64 Billion CNY | 27.92% |
| 2019 Q3 | 5.45 Billion CNY | 3.47% |
| 2019 Q2 | 5.27 Billion CNY | 6.2% |
| 2019 Q1 | 4.96 Billion CNY | 12.4% |
| 2018 FY | 4.41 Billion CNY | 23.86% |
| 2018 Q1 | 3.96 Billion CNY | 11.31% |
| 2018 Q2 | 3.99 Billion CNY | 0.68% |
| 2018 Q3 | 4.35 Billion CNY | 9.01% |
| 2018 Q4 | 4.41 Billion CNY | 1.39% |
| 2017 Q1 | 2.29 Billion CNY | 7.45% |
| 2017 Q2 | 3.1 Billion CNY | 35.45% |
| 2017 FY | 3.56 Billion CNY | 67.16% |
| 2017 Q4 | 3.56 Billion CNY | -6.02% |
| 2017 Q3 | 3.79 Billion CNY | 22.22% |
| 2016 Q4 | 2.13 Billion CNY | -16.83% |
| 2016 Q3 | 2.56 Billion CNY | -9.28% |
| 2016 Q2 | 2.82 Billion CNY | -1.64% |
| 2016 Q1 | 2.87 Billion CNY | 7.14% |
| 2016 FY | 2.13 Billion CNY | -20.49% |
| 2015 Q3 | 2.76 Billion CNY | 0.0% |
| 2015 Q4 | 2.68 Billion CNY | -2.89% |
| 2015 FY | 2.68 Billion CNY | 0.69% |
| 2015 Q1 | - CNY | 0.0% |
| 2014 FY | 2.66 Billion CNY | 17.5% |
| 2013 FY | 2.26 Billion CNY | 27.67% |
| 2012 FY | 1.77 Billion CNY | 82.53% |
| 2011 FY | 973.16 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Cachet Pharmaceutical Co., Ltd. | 11.02 Billion CNY | 20.062% |
| Yixintang Pharmaceutical Group Co., Ltd. | 8.75 Billion CNY | -0.681% |
| ZJAMP Group Co., Ltd. | 12.99 Billion CNY | 32.146% |
| Ji Yao Holding Group Co., Ltd. | 2.72 Billion CNY | -224.03% |